Single Peptide1mgResearch-Based Protocol

IGF-1 LR3 (1mg) Dosage Protocol

IGF-1 LR3 (Long R3 IGF-1) is a modified version of insulin-like growth factor-1 with an extended half-life. The arginine substitution and 13 amino acid extension reduce binding to IGF binding proteins.

Quickstart Highlights
Reconstitute

Add 1.0 mL bacteriostatic water → 1 mg/mL (1000 mcg/mL)

Daily Range

20-60 mcg daily, post-workout or split doses

Easy Measuring

At 1 mg/mL: 2 units = 20 mcg, 6 units = 60 mcg

Storage

Lyophilized: -20°C; Reconstituted: 2-8°C for up to 4 weeks

Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing based on research literature
WeekDaily DoseUnits (per injection)
Weeks 1-220 mcg daily2 units post-workout
Weeks 3-440 mcg daily4 units post-workout
Weeks 5-650-60 mcg daily5-6 units post-workout
Reconstitution Steps
  1. 1Draw 1.0 mL bacteriostatic water with a sterile syringe
  2. 2Inject slowly down the vial wall to prevent foaming
  3. 3Gently swirl until fully dissolved - do not shake
  4. 4Label with date and concentration, refrigerate immediately
How This Works

IGF-1 LR3 has reduced affinity for IGF binding proteins, resulting in longer half-life and greater bioavailability than native IGF-1. It activates the IGF-1 receptor, promoting protein synthesis, cell growth, and nutrient uptake in muscle tissue.

Potential Benefits & Effects
Observations from preclinical and clinical literature
  • Extended half-life vs native IGF-1
  • Promotes protein synthesis
  • May support muscle hyperplasia
  • Enhanced nutrient partitioning
Scientific References
Published research supporting this protocol
  1. Francis GL, et al. Novel recombinant IGF-1 analogs. Endocrinology. 1992
  2. Tomas FM, et al. Effects of IGF-1 on muscle. J Endocrinol. 1993
  3. IGF-1 LR3 research and muscle protein synthesis studies
Storage Instructions

Lyophilized

Store at -20°C, protected from light

Reconstituted

Refrigerate at 2-8°C, use within 4 weeks

Cycle on/off to prevent receptor desensitization

Important Notes
  • Research compound - not FDA approved
  • May cause hypoglycemia - monitor blood sugar
  • Cycle 4-6 weeks on, 4 weeks off
  • Start with lowest effective dose

Disclaimer: This content is intended for research and educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. All compounds are for research use only. Dosing information is derived from published scientific literature and clinical studies.